Table 2 Timing of outcome measures.

From: A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome

 

Week 0

Week 4

Week 8

Week 12

Week 16

Week 24

Outcome Measure

Baseline

 

Midpoint

 

Endpoint

Follow-up

Primary

HbA1c

 

 

FPG

 

 

Secondary

Blood pressure

 

 

Triglycerides

 

 

Waist circumference

 

 

Hip circumference

 

 

BMI

 

 

SF-36

 

 

C-RP

 

 

Total cholesterol

 

 

HDL

 

 

LDL

 

 

Apolipoprotein A

   

 

Apolipoprotein B

   

 
  1. BMI = Body Mass Index, HDL-C = High Density Lipoprotein Cholesterol, C-RP = C-reactive protein, LDL = Low Density Lipoprotein Cholesterol.